ciglitazone has been researched along with fenofibrate in 12 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 8 (66.67) | 29.6817 |
2010's | 4 (33.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Blaschke, F; Bungenstock, A; Eilers, F; Fleck, E; Goetze, S; Graf, K; Gräfe, M; Kintscher, U; Law, RE; Stawowy, P | 1 |
Greenberg, AS; Mathys, JM; Rabbi, MF; Skolnik, PR | 1 |
Gille, J; Kaufmann, R; Meissner, M; Reisinger, K; Staels, B; Stein, M; Suske, G; Urbich, C | 1 |
Buckley, KA; Chan, BY; Dillon, JP; Fraser, WD; Gallagher, JA; Gartland, A; Wilson, PJ | 1 |
Carissimi, R; Galli, C; Ghezzi, S; Mastromauro, F; Petroni, A; Risé, P | 1 |
Oku, H; Umino, T | 1 |
Chopra, B; Georgopoulos, NT; Hinley, J; Nicholl, A; Oleksiewicz, MB; Southgate, J | 1 |
12 other study(ies) available for ciglitazone and fenofibrate
Article | Year |
---|---|
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
PPAR activators inhibit endothelial cell migration by targeting Akt.
Topics: Apoptosis; Blotting, Western; Cell Movement; Cells, Cultured; Chromans; Endothelial Growth Factors; Endothelium, Vascular; Enzyme Inhibitors; Fenofibrate; Flavonoids; Humans; Hypoglycemic Agents; Hypolipidemic Agents; In Situ Nick-End Labeling; Lipid Metabolism; Lymphokines; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Peroxisome Proliferators; Phosphatidylinositol 3-Kinases; Phosphorylation; Pyrimidines; Receptors, Cytoplasmic and Nuclear; Signal Transduction; Thiazoles; Thiazolidinediones; Time Factors; Transcription Factors; Troglitazone; Umbilical Veins; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Vasodilator Agents | 2002 |
Stimulation of peroxisome proliferator-activated receptors alpha and gamma blocks HIV-1 replication and TNFalpha production in acutely infected primary blood cells, chronically infected U1 cells, and alveolar macrophages from HIV-infected subjects.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Cell Line; Chromans; Fenofibrate; HIV-1; Humans; Leukocytes, Mononuclear; Macrophages, Alveolar; Prostaglandin D2; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone; Tumor Necrosis Factor-alpha; Virus Replication | 2002 |
PPARalpha activators inhibit vascular endothelial growth factor receptor-2 expression by repressing Sp1-dependent DNA binding and transactivation.
Topics: Binding Sites; Cell Division; Cells, Cultured; Endothelial Cells; Fenofibrate; Gene Expression Regulation; Humans; Luciferases; Neovascularization, Physiologic; Peroxisome Proliferators; Promoter Regions, Genetic; Protein Binding; Pyrimidines; Receptors, Cytoplasmic and Nuclear; Recombinant Fusion Proteins; RNA, Messenger; Rosiglitazone; Sp1 Transcription Factor; Thiazolidinediones; Transcription Factors; Transcriptional Activation; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2004 |
PPAR agonists modulate human osteoclast formation and activity in vitro.
Topics: Acetates; Apoptosis; Bezafibrate; Bone Resorption; Butyrates; Cells, Cultured; Fenofibrate; Humans; Hypolipidemic Agents; Leukocytes, Mononuclear; Macrophage Colony-Stimulating Factor; Osteoclasts; Peroxisome Proliferator-Activated Receptors; Phenols; Phenoxyacetates; Phenylurea Compounds; RANK Ligand; RNA, Messenger; Thiazolidinediones; Transcription, Genetic | 2007 |
Delta5 desaturase mRNA levels are increased by simvastatin via SREBP-1 at early stages, not via PPARalpha, in THP-1 cells.
Topics: Anticholesteremic Agents; Arachidonic Acid; Cell Line; Cholesterol; Delta-5 Fatty Acid Desaturase; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Induction; Fatty Acid Desaturases; Fenofibrate; Humans; Linoleic Acid; Lipid Metabolism; Monocytes; Peroxisome Proliferators; PPAR alpha; PPAR gamma; Pyrimidines; RNA, Messenger; Simvastatin; Sterol Regulatory Element Binding Protein 1; Thiazolidinediones; Time Factors; Transcription, Genetic | 2007 |
Molecular characterization of peroxisome proliferator-activated receptors (PPARs) and their gene expression in the differentiating adipocytes of red sea bream Pagrus major.
Topics: Adipocytes; Animals; Cell Differentiation; Cells, Cultured; Fenofibrate; Hypoglycemic Agents; Peroxisome Proliferator-Activated Receptors; Phylogeny; Prostaglandin D2; Protein Isoforms; Sea Bream; Thiazolidinediones | 2008 |
Structurally diverse peroxisome proliferator-activated receptor agonists induce apoptosis in human uro-epithelial cells by a receptor-independent mechanism involving store-operated calcium channels.
Topics: Apoptosis; Calcium; Calcium Channels; Caspase 3; Caspase 9; Cell Division; Cells, Cultured; Chromans; Epithelial Cells; Extracellular Signal-Regulated MAP Kinases; Fenofibrate; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Membrane Potential, Mitochondrial; Oxazines; p38 Mitogen-Activated Protein Kinases; Peroxisome Proliferator-Activated Receptors; Phenoxyacetates; Phenylpropionates; Rosiglitazone; Thiazolidinediones; Troglitazone; Urothelium | 2009 |